This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Porotto, M.
Right arrow Articles by Moscona, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Porotto, M.
Right arrow Articles by Moscona, A.

 Previous Article  |  Next Article 

Journal of Virology, December 2004, p. 13911-13919, Vol. 78, No. 24
0022-538X/04/$08.00+0     DOI: 10.1128/JVI.78.24.13911-13919.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Inhibition of Parainfluenza Virus Type 3 and Newcastle Disease Virus Hemagglutinin-Neuraminidase Receptor Binding: Effect of Receptor Avidity and Steric Hindrance at the Inhibitor Binding Sites

Matteo Porotto,1 Matthew Murrell,1 Olga Greengard,1 Michael C. Lawrence,2 Jennifer L. McKimm-Breschkin,2 and Anne Moscona1*

Department of Pediatrics, Mount Sinai School of Medicine, New York, New York,1 CSIRO Health Sciences and Nutrition, Parkville, Victoria, Australia2

Received 10 June 2004/ Accepted 9 August 2004

Zanamivir (4-guanidino-Neu5Ac2en [4-GU-DANA]) inhibits not only the neuraminidase activity but also the receptor interaction of the human parainfluenza virus type 3 (HPIV3) hemagglutinin-neuraminidase (HN), blocking receptor binding and subsequent fusion promotion. All activities of the HPIV3 variant ZM1 HN (T193I/I567V) are less sensitive to 4-GU-DANA's effects. The T193I mutation in HN confers both increased receptor binding and increased neuraminidase activity, as well as reduced sensitivities of both activities to 4-GU-DANA inhibition, consistent with a single site on the HN molecule carrying out both catalysis and binding. We now provide evidence that the HPIV3 variant's resistance to receptor-binding inhibition by 4-GU-DANA is related to a reduced affinity of the HN receptor-binding site for this compound as well as to an increase in the avidity of HN for the receptor. Newcastle disease virus (NDV) HN and HPIV3 HN respond differently to inhibition in ways that suggest a fundamental distinction between them. NDV HN-receptor binding is less sensitive than HPIV3 HN-receptor binding to 4-GU-DANA, while its neuraminidase activity is highly sensitive. Both HPIV3 and NDV HNs are sensitive to receptor-binding inhibition by the smaller molecule DANA. However, for NDV HN, some receptor binding cannot be inhibited. These data are consistent with the presence in NDV HN of a second receptor-binding site that is devoid of enzyme activity and has a negligible, if any, affinity for 4-GU-DANA. Avidity for the receptor contributes to resistance by allowing the receptor to compete effectively with inhibitors for interaction with HN, while the further determinant of resistance is the reduced binding of the inhibitor molecule to the binding pocket on HN. Based upon our data and recent three-dimensional structural information on the HPIV3 and NDV HNs, we propose mechanisms for the observed sensitivity and resistance of HN to receptor-binding inhibition and discuss the implications of these mechanisms for the distribution of HN functions.

* Corresponding author. Mailing address: Department of Pediatrics, Mount Sinai School of Medicine, 1 Gustave L. Levy Pl., New York, NY 10029. Phone: (212) 241-9709. Fax: (212) 860-3316. E-mail: Anne.moscona{at}mssm.edu.

Journal of Virology, December 2004, p. 13911-13919, Vol. 78, No. 24
0022-538X/04/$08.00+0     DOI: 10.1128/JVI.78.24.13911-13919.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Palermo, L. M., Porotto, M., Yokoyama, C. C., Palmer, S. G., Mungall, B. A., Greengard, O., Niewiesk, S., Moscona, A. (2009). Human Parainfluenza Virus Infection of the Airway Epithelium: Viral Hemagglutinin-Neuraminidase Regulates Fusion Protein Activation and Modulates Infectivity. J. Virol. 83: 6900-6908 [Abstract] [Full Text]  
  • Porotto, M., Orefice, G., Yokoyama, C. C., Mungall, B. A., Realubit, R., Sganga, M. L., Aljofan, M., Whitt, M., Glickman, F., Moscona, A. (2009). Simulating Henipavirus Multicycle Replication in a Screening Assay Leads to Identification of a Promising Candidate for Therapy. J. Virol. 83: 5148-5155 [Abstract] [Full Text]  
  • Alymova, I. V., Taylor, G., Mishin, V. P., Watanabe, M., Murti, K. G., Boyd, K., Chand, P., Babu, Y. S., Portner, A. (2008). Loss of the N-Linked Glycan at Residue 173 of Human Parainfluenza Virus Type 1 Hemagglutinin-Neuraminidase Exposes a Second Receptor-Binding Site. J. Virol. 82: 8400-8410 [Abstract] [Full Text]  
  • Nichols, W. G., Peck Campbell, A. J., Boeckh, M. (2008). Respiratory Viruses Other than Influenza Virus: Impact and Therapeutic Advances. Clin. Microbiol. Rev. 21: 274-290 [Abstract] [Full Text]  
  • Porotto, M., Carta, P., Deng, Y., Kellogg, G. E., Whitt, M., Lu, M., Mungall, B. A., Moscona, A. (2007). Molecular Determinants of Antiviral Potency of Paramyxovirus Entry Inhibitors. J. Virol. 81: 10567-10574 [Abstract] [Full Text]  
  • Palermo, L. M., Porotto, M., Greengard, O., Moscona, A. (2007). Fusion Promotion by a Paramyxovirus Hemagglutinin-Neuraminidase Protein: pH Modulation of Receptor Avidity of Binding Sites I and II. J. Virol. 81: 9152-9161 [Abstract] [Full Text]  
  • Porotto, M., Fornabaio, M., Kellogg, G. E., Moscona, A. (2007). A Second Receptor Binding Site on Human Parainfluenza Virus Type 3 Hemagglutinin-Neuraminidase Contributes to Activation of the Fusion Mechanism. J. Virol. 81: 3216-3228 [Abstract] [Full Text]  
  • Porotto, M., Doctor, L., Carta, P., Fornabaio, M., Greengard, O., Kellogg, G. E., Moscona, A. (2006). Inhibition of Hendra Virus Fusion. J. Virol. 80: 9837-9849 [Abstract] [Full Text]  
  • Bousse, T., Takimoto, T. (2006). Mutation at residue 523 creates a second receptor binding site on human parainfluenza virus type 1 hemagglutinin-neuraminidase protein.. J. Virol. 80: 9009-9016 [Abstract] [Full Text]  
  • Porotto, M., Fornabaio, M., Greengard, O., Murrell, M. T., Kellogg, G. E., Moscona, A. (2006). Paramyxovirus Receptor-Binding Molecules: Engagement of One Site on the Hemagglutinin-Neuraminidase Protein Modulates Activity at the Second Site. J. Virol. 80: 1204-1213 [Abstract] [Full Text]  
  • Lopez-Bueno, A., Rubio, M.-P., Bryant, N., McKenna, R., Agbandje-McKenna, M., Almendral, J. M. (2006). Host-Selected Amino Acid Changes at the Sialic Acid Binding Pocket of the Parvovirus Capsid Modulate Cell Binding Affinity and Determine Virulence. J. Virol. 80: 1563-1573 [Abstract] [Full Text]  
  • Rubio, M.-P., Lopez-Bueno, A., Almendral, J. M. (2005). Virulent Variants Emerging in Mice Infected with the Apathogenic Prototype Strain of the Parvovirus Minute Virus of Mice Exhibit a Capsid with Low Avidity for a Primary Receptor. J. Virol. 79: 11280-11290 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»